PUNE, MH, INDIA, July 16, 2022 /EINPresswire.com/ -- While clinical trials encompass the foundational steps towards the potential widespread availability of drugs post-approval, a number of factors based on demographics, co-morbidities, environmental impact, food habits & routines or habits can end up being overlooked which affect the efficacy & suitability of a certain drug/treatment for a particular patient.

The 5th Annual MARKETSANDMARKETS REAL-WORLD EVIDENCE & LIFE SCIENCES ANALYTICS CONFERENCE shall play host to expert researchers working deep in the field, who have had a chance to reflect on the changing framework of real world data (RWD) collection as impacted by the pandemic years. Advancements in technology has facilitated adoption of smart devices like wearables & digital health trackers allowing pharma companies to generate real world evidence (RWE) by analyzing a wide spectrum of datapoints from new & novel sources apart from the usual electronic health records, patient billing records, admin or insurance claims and patient-generated health data.

Scheduled for the 20th - 21st of OCTOBER 2022 in BOSTON - USA, the conference provides a great opportunity to connect & discuss thought provoking topics with peers in the community while imbibing invaluable insights from intricately crafted presentations by industry leaders!

A SNIPPET OF TOPICS TO BE DISCUSSED AT THE CONFERENCE

• Regulatory view around data quality & data standards.
• Leveraging RWE to improve market access.
• The adoption & role of AI & ML in clinical trials.
• The expanded role of Real World Evidence for Digital Health.
• Panel Discussion on lessons learned from the recent results of the FDA’s
• Pilot program RCT DUPLICATE.
• Real-World Data & Advanced Analytics.
• RWE to inform decision making process in rare diseases where there is lack of evidence.

INTRODUCING THE ESTEEMED PANEL OF SPEAKERS

• CHARLES MAKIN, Global Head, Real World Evidence Strategy, BIOGEN
• JOEL IFF, Senior Director Global Market Access, SAREPTA THERAPEUTICS, USA
• MELVA COVINGTON, Senior Vice President, Research and Patient Outcomes, CURIO DIGITAL THERAPEUTICS
• NNEKA ONWUDIWE, Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION
• HUAN HUANG, Director, HEOR, G1 THERAPEUTICS, INC.
• JENNIFER WEBSTER, Senior Director, Precision Medicine RWE Lead, PFIZER
• ERIC SARPONG, Director, Real-World Data Analytics and Innovation, Centre for Observation and Real-World Evidence (CORE), MERCK

LEAF THROUGH THE ENTIRE 2-DAY AGENDA HERE!
REGISTER FOR THE CONFERENCE TODAY!

Ayush Kanitkar
MarketsandMarkets
+91 89759 85061
events@marketsandmarkets.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.